Biotech’s op­ti­mism is re­turn­ing amid signs of a bet­ter sec­ond half and a brighter 2024

Odysseus even­tu­al­ly made it to shore, as Bridge­Bio CEO Neil Ku­mar re­mind­ed the in­dus­try last Fri­day in a nod to Homer’s clas­sic tale. And on Mon­day, his biotech cel­e­brat­ed a key Phase III win, putting wind in its sails for a trip to the FDA.

Biotechs every­where are hop­ing for a sim­i­lar mo­ment in the sun af­ter a two-year trou­bled odyssey be­set by low rounds of pri­vate fi­nanc­ing, mis­aligned val­u­a­tion ex­pec­ta­tions, a large­ly un­re­ward­ing pub­lic mar­ket and a dearth of IPOs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER